November 27, 2018
Kyowa Hakko Kirin said on November 26 that its anti-CCR4 monoclonal antibody Poteligeo (mogamulizumab) was approved in Europe for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. The...read more